Trial reportLeukemia2016
Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.
Trial report in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.Clinical pharmacokinetics · 2020Trial
- A next-generation sequencing-based assay for minimal residual disease assessment in AML patients withBlood advances · 2018Trial
- Prognostic Significance of Secondary-Type Mutations in NPM1-Mutated Acute Myeloid Leukemia.Cancer medicine · 2026Article
- Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome.Internal medicine (Tokyo, Japan) · 2026Article
- Review
- Article
- Allogeneic hematopoietic stem cell transplantation could overcome the poor prognosis of DNMT3AFrontiers of medicine · 2025Article
- Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia.International journal of hematology · 2025Article
- Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Journal of hematology & oncology · 2024Review
- FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.Leukemia · 2024Article
- Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes.Cell genomics · 2023Article
- Review
- Evaluation of hypereosinophilia in a case ofCold Spring Harbor molecular case studies · 2023Article
- Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results.Mediterranean journal of hematology and infectious diseases · 2023Article
- Alterations toCancer research · 2021Review
- Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.PloS one · 2021Article
- Gilteritinib: potent targeting of FLT3 mutations in AML.Blood advances · 2020Review
- Gilteritinib induces differentiation in relapsed and refractoryBlood advances · 2019Article
- New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.International journal of molecular sciences · 2019Review
- Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.